Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy
Authors:
- 8 November 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 112 (19) , 2980-2985
Abstract
Background— Vasodilatory therapy of Raynaud’s phenomenon represents a difficult clinical problem because treatment often remains inefficient and may be not tolerated because of side effects. Methods and Results— To investigate the effects of sildenafil on symptoms and capillary perfusion in patients with Raynaud’s phenomenon, we performed a double-blinded, placebo-controlled, fixed-dose, crossover study in 16 patients with symptomatic secondary Raynaud’s phenomenon resistant to vasodilatory therapy. Patients were treated with 50 mg sildenafil or placebo twice daily for 4 weeks. Symptoms were assessed by diary cards including a 10-point Raynaud’s Condition Score. Capillary flow velocity was measured in digital nailfold capillaries by means of a laser Doppler anemometer. While taking sildenafil, the mean frequency of Raynaud attacks was significantly lower (35±14 versus 52±18, P =0.0064), the cumulative attack duration was significantly shorter (581±133 versus 1046±245 minutes, P =0.0038), and the mean Raynaud’s Condition Score was significantly lower (2.2±0.4 versus 3.0±0.5, P =0.0386). Capillary blood flow velocity increased in each individual patient, and the mean capillary flow velocity of all patients more than quadrupled after treatment with sildenafil (0.53±0.09 versus 0.13±0.02 mm/s, P =0.0004). Two patients reported side effects leading to discontinuation of the study drug. Conclusions— Sildenafil is an effective and well-tolerated treatment in patients with Raynaud’s phenomenon.Keywords
This publication has 19 references indexed in Scilit:
- Use of sildenafil citrate in Raynaud's phenomenon: Comment on the article by Thompson et alArthritis & Rheumatism, 2003
- The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemiaJACC, 2002
- Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenonArthritis & Rheumatism, 2002
- Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 DiabetesDiabetes Care, 2002
- Erectile DysfunctionNew England Journal of Medicine, 2000
- Oral Sildenafil in the Treatment of Erectile DysfunctionNew England Journal of Medicine, 1998
- Nitric oxide mediates contraction‐induced attenuation of sympathetic vasoconstriction in rat skeletal muscleThe Journal of Physiology, 1998
- Capillary Blood Cell Velocity in Human Skin Capillaries Located Perpendicularly to the Skin Surface: Measured by a New Laser Doppler AnemometerMicrovascular Research, 1996
- Raynaudʼs phenomenonCurrent Opinion in Rheumatology, 1993
- Prevalence of symptoms of Raynaud's phenomenon in general practice.BMJ, 1990